| TRADING CENTER |
| Genzyme's Termeer: Worst Biotech CEO of '09 - at TheStreet.com | |
| Osiris Posts Loss - Analyst Blog - Zacks.com | |
| Osiris Therapeutics Reports Third Quarter 2009 Financial Results - Business Wire | |
| Osiris Therapeutics Achieves $15 Million Milestone Payment - Business Wire | |
| Integrity Media: Stem Cell Report Released - GlobeNewswire |
| Last trade | Change/%change | P/E ratio | ||
|---|---|---|---|---|
| AMGN | Amgen Inc | 56.25 | 0.87 / 1.57% | 10.76 |
| GILD | Gilead Sciences Inc | 47.01 | 0.62 / 1.34% | 18.15 |
| CELG | Celgene Corporation | 55.65 | 0.74 / 1.35% | 67.05 |
| 2008 Revenue: | $10.0 M | Headquarters: Columbia, MD |
| Employees: | 163 | CEO: Dr. C. Randal Mills, Ph.D. |
| Net Income: | $-33,492,000.0 | Industry: Biotechnology |
| Market Cap: | $215.3 M | Website: www.osiristx.com |
| Symbol | Price | Change/%Change | Prev. close | High | Low | Last Update | More Info |
|---|---|---|---|---|---|---|---|
| OSIR | 6.54 | -0.03 / -0.46% | 6.57 | 6.69 | 6.46 | Profile Chart News |